Research progress of nicorandil in prevention of contrast agent-related acute renal injury in patients with coronary intervention / 中国综合临床
Clinical Medicine of China
;
(12): 140-144, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-992482
ABSTRACT
With the rapid development of imaging and percutaneous coronary intervention, the application of contrast media has become more and more widespread, and contrast-associated AKI has become one of the most common causes of acute kidney injury. Contrast-associated AKI seriously threatens patients' health and brings greater economic burden to patients, so it is particularly important to prevent the contrast-associated AKI. Nicorandil is a common vasodilator drug in clinical practice, widely used in the treatment of angina pectoris, with the effects of anti-oxidative stress, anti-apoptosis, anti-inflammatory and vasodilation, and is considered to be effective in preventing contrast - associated AKI. However, there is still a lack of further research on the efficacy of nicorandil in preventing contrast-associated AKI.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Clinical Medicine of China
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS